M
Matthew Oughton
Researcher at McGill University
Publications - 22
Citations - 3158
Matthew Oughton is an academic researcher from McGill University. The author has contributed to research in topics: Clostridium difficile & Medicine. The author has an hindex of 10, co-authored 21 publications receiving 2990 citations. Previous affiliations of Matthew Oughton include Jewish General Hospital.
Papers
More filters
Journal ArticleDOI
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.
Vivian G. Loo,Louise Poirier,Mark A. Miller,Matthew Oughton,Michael Libman,Sophie Michaud,Anne-Marie Bourgault,Tuyen Nguyen,Charles Frenette,Mirabelle Kelly,Anne Vibien,Paul Brassard,Susan Fenn,Ken Dewar,Thomas J. Hudson,Ruth Horn,Pierre René,Yury Monczak,Andre Dascal +18 more
TL;DR: A strain of C. difficile that was resistant to fluoroquinolones and had binary toxin and a partial deletion of the tcdC gene was responsible for this outbreak ofC.difficile-associated diarrhea.
Journal ArticleDOI
Host and Pathogen Factors for Clostridium difficile Infection and Colonization
Vivian G. Loo,Anne-Marie Bourgault,Louise Poirier,François Lamothe,Sophie Michaud,Nathalie Turgeon,Baldwin Toye,Axelle Beaudoin,Eric Frost,Rodica Gilca,Paul Brassard,Nandini Dendukuri,Claire Béliveau,Matthew Oughton,Ivan Brukner,Andre Dascal +15 more
TL;DR: Health care-associated C. difficile infection and colonization were differentially associated with defined host and pathogen variables, whereas asymptomatic patients were more likely to be colonized with other strains.
Journal ArticleDOI
Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile.
TL;DR: Handwashing with soap and water showed the greatest efficacy in removing C. difficile and should be performed preferentially over the use of alcohol-based handrubs when contact with C. Difficile is suspected or likely.
Journal ArticleDOI
Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
Richard Vickers,Glenn S. Tillotson,Richard Nathan,Sabine Hazan,John Pullman,Christopher Lucasti,Kenneth Deck,Bruce R. Yacyshyn,Benedict Maliakkal,Yves Pesant,Bina Tejura,David Roblin,Dale N. Gerding,Mark H. Wilcox,Amit Bhan,Wayne Campbell,Teena Chopra,Yoav Golan,Ian Gordon,Ravi Kamepalli,Sahil Khanna,Christine H. Lee,Irene Minang,Kathleen M. Mullane,Matthew Oughton,John Phillips,Paul Riska,Christian Schrock,Jonathan Siegel,Alon Steinberg,David A. Talan,Stephen Tamang,Michael Tan,Karl Weiss,Chia Wang,Jo Anne H. Young,Jonathan Zenilman +36 more
TL;DR: Rinilazole is a targeted-spectrum antimicrobial that shows potential in treatment of initial C difficile infection and in providing sustained benefit through reduction in disease recurrence through statistical superiority at the 10% level.
Journal ArticleDOI
Fourteen-Genome Comparison Identifies DNA Markers for Severe-Disease-Associated Strains of Clostridium difficile
Vincenzo Forgetta,Matthew Oughton,Pascale Marquis,Ivan Brukner,Ruth Blanchette,Kevin Haub,Vince Magrini,Elaine R. Mardis,Dale N. Gerding,Vivian G. Loo,Mark A. Miller,Michael R. Mulvey,Maja Rupnik,Andre Dascal,Ken Dewar +14 more
TL;DR: The genetic markers identified illustrate the potential of comparative genomics for the discovery of diagnostic DNA-based targets that are species specific or associated with multiple SDA strains.